CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
- The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions
- CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively
- CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021
- At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin
- Virtual event participation can be found on the CNS website under “Events”
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently participated in the 2022 Virtual Growth Conference presented by the Maxim Group LLC and hosted by M-Vest from March 28-30. CEO of CNS, John Climaco, represented the company, sharing the corporate presentation and participating in a fireside chat that was moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group. The CNS corporate presentation was made available on-demand to those attending the virtual summit.
The conference is a platform for investors to hear from company executives from a vast array of sectors, including biotech, clean energy, electric vehicles (“EV”), financial services, fintech, REITS, gaming, entertainment, healthcare, healthcare IT, and more. The three-day event showcased CNS and other participants’ strengths through corporate presentations, fireside chats, roundtable discussions, and live question and answer sessions with the CEOs by Maxim Research Analysts.
CNS’ lead drug for glioblastoma multiforme is Berubicin, a novel anthracycline that is the first in its class capable of crossing the blood-brain barrier. A Phase 1 clinical trial for Berubicin was completed by Reata Pharmaceuticals Inc. almost 14 years ago. Since then, one patient has been free of cancer, and two more saw tumor reduction of up to 80%. CNS has since gained FDA Fast Track designation for Berubicin (June 2021) and FDA Orphan Drug Designation (2020).
CNS recently gained approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a potentially pivotal glioblastoma multiforme study with Berubicin. Climaco commented on this achievement, saying it was a significant milestone for the company. “Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally. This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do but how we do it as well,” the CNS CEO added (https://nnw.fm/atsi3).
The company is also working on developing its WP1244 drug technology portfolio, utilizing anthracycline and distamycin-based structure to create small molecular agents. These agents are believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies have demonstrated a high uptake in antitumor activity. CNS will evaluate its use in the treatment of multiple cancers including brain, pancreatic, ovarian, and lymphoma.
In recent months, Climaco participated in other virtual events, including Virtual Investor 2022 Top Picks Conference and H.C. Wainwright BioConnect Conference. During these events, Climaco shared the company’s corporate presentation, participated in moderated question and answer sessions, and discussed the company’s future with Berubicin. The video webcast of the 2022 Top Picks Conference is available online for one year and can be accessed through the “Events” page on the CNS website.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions
- CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively
- CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021
- At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin
- Virtual event participation can be found on the CNS website under “Events”
CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently participated in the 2022 Virtual Growth Conference presented by the Maxim Group LLC and hosted by M-Vest from March 28-30. CEO of CNS, John Climaco, represented the company, sharing the corporate presentation and participating in a fireside chat that was moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group. The CNS corporate presentation was made available on-demand to those attending the virtual summit.
The conference is a platform for investors to hear from company executives from a vast array of sectors, including biotech, clean energy, electric vehicles (“EV”), financial services, fintech, REITS, gaming, entertainment, healthcare, healthcare IT, and more. The three-day event showcased CNS and other participants’ strengths through corporate presentations, fireside chats, roundtable discussions, and live question and answer sessions with the CEOs by Maxim Research Analysts.
CNS’ lead drug for glioblastoma multiforme is Berubicin, a novel anthracycline that is the first in its class capable of crossing the blood-brain barrier. A Phase 1 clinical trial for Berubicin was completed by Reata Pharmaceuticals Inc. almost 14 years ago. Since then, one patient has been free of cancer, and two more saw tumor reduction of up to 80%. CNS has since gained FDA Fast Track designation for Berubicin (June 2021) and FDA Orphan Drug Designation (2020).
CNS recently gained approval from swissethics, the umbrella organization of the cantonal Ethics Committee in Switzerland, for a potentially pivotal glioblastoma multiforme study with Berubicin. Climaco commented on this achievement, saying it was a significant milestone for the company. “Our stated goal is, and always has been, to see Berubicin approved for the treatment of glioblastoma, and this means globally. This terrible disease does not discriminate on the basis of geography or anything else: Patients in Europe are as desperate as patients in the United States, and treating patients is not only why we do what we do but how we do it as well,” the CNS CEO added (https://nnw.fm/atsi3).
The company is also working on developing its WP1244 drug technology portfolio, utilizing anthracycline and distamycin-based structure to create small molecular agents. These agents are believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies have demonstrated a high uptake in antitumor activity. CNS will evaluate its use in the treatment of multiple cancers including brain, pancreatic, ovarian, and lymphoma.
In recent months, Climaco participated in other virtual events, including Virtual Investor 2022 Top Picks Conference and H.C. Wainwright BioConnect Conference. During these events, Climaco shared the company’s corporate presentation, participated in moderated question and answer sessions, and discussed the company’s future with Berubicin. The video webcast of the 2022 Top Picks Conference is available online for one year and can be accessed through the “Events” page on the CNS website.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
